SpringWorks Therapeutics, Inc. SWTX expanded its existing clinical collaboration agreement with GSK GSK. The partnership is evaluating the combination of SpringWorks’ investigational oral gamma ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck KGaA has agreed to buy biotechnology company ...
Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancers Financials include a $13 million upfront payment and potential for ...
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European ...
SpringWorks Therapeutics received FDA approval for its oral gamma secretase inhibitor Ogsiveo, for the treatment of adult patients with desmoid tumors. The approval is based on positive results from ...
– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add ...
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.76% By Investing.com - May 27, 2022 Investing.com – U.S. stocks were higher after the close on Friday, as gains in the ...
Stocktwits on MSN
Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets
Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation ...
STAMFORD, Conn., Dec. 04, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced ...
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per ...
SpringWorks Therapeutics has established itself as a promising player in the U.S. Small & Mid Cap Biotechnology sector. The company’s primary focus has been on developing innovative therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback